Loading ...
the required period maintenance feescausingthe patent to expire
Someoneinventedthe patent expire
knowhas ledto some minor patent expiration
Streptococcus two gram dosage of zithromax with levoflaxacin via the liver caution(passive) caused byzithromax patent expiration
by the need to obtain a marketing authorisation before the product can be marketed(passive) caused bypatent term
by the need to obtain a marketing authorisation(passive) caused bypatent term
with smoke(passive) is often paintedPatent term
by applicant 's delay(passive) caused bypatent term
Failure to pay the current maintenance fee on timemay resultin expiration of the patent
Failure to pay the current maintenance fee on timemay resultin expiration of the patent
by injury(passive) caused bylansoprazole patent expiration
the effectcausea looming patent expiration
A patent may not have its term extended after the termination of the patent term , therefore failure to file an applicationwill resultin the expiration of the patent
Failure to pay the feemay resultin expiration of the patent
DrugscausedPatent Ductus
arteriosus(passive) can be causedPatent ductus
the riskresultingfrom patent expiration
the loss in profitresultedfrom the expiration of the patent
these deadlinesmay resultin expiration of the patent
the dedicationresultingfrom the expiration of the patents
the time necessary to process and review an application for patent term extensionmight resultin a patent expiring
Profits lossesresultingfrom patent expiry
the term of a patent for up to one year if the time necessary to process and review an application for patent term extensionmight resultin a patent expiring
Revenue lossesresultingfrom patent expiry
maintenance fees ... the patent officeresultsin the patent expiring
Failure to pay the maintenance fee on timewill resultin the patent expiring
of rights granted to an inventor by national government for some time period in exchange of public disclosure of that invention(passive) is setPatent
the first Irish companyto designpatent
to protect and encourage innovation(passive) was inventedPatent
patents are being invented(passive) was inventedpatent
to protect ideas , systems , or methods of operation(passive) is designedPatent
an interest in any patent application orresultingpatent
The identity of inventors in a patent application has a bearing on ownership of the invention andresultingpatent
to expire(passive) is currently setpatent
by its inventor(passive) was contributed bypatent
informationto resultpatent
Inc. Design which is not entitledto designpatent
Our firmhas inventedpatent
this issue ... enoughto designpatent
the problemcausingpatent
to a rapid increase in the number of newly treated patientsledto a rapid increase in the number of newly treated patients
paincausingpain
sales to decline , or new competition , which we 'll talk about in a second , or new drug launchescausingsales to decline , or new competition , which we 'll talk about in a second , or new drug launches
to a rapid increase in the number of newly treated patients , with an appreciable number prescribed generic atorvastatin ( 50.9 % in June 2010ledto a rapid increase in the number of newly treated patients , with an appreciable number prescribed generic atorvastatin ( 50.9 % in June 2010
in particularcan resultin particular
in the sluggish growth rate of the adalimumab market in Latin Americahas resultedin the sluggish growth rate of the adalimumab market in Latin America
in the sluggish growth rate of the adalimumab market in Latin Americahas resultedin the sluggish growth rate of the adalimumab market in Latin America
within - patent competition(passive) caused bywithin - patent competition
enough competition in the markethas ... causedenough competition in the market
to price competitionthereby leadingto price competition
the loss(passive) caused bythe loss
in limited generic competitionresultsin limited generic competition
to massive revenue lossescan leadto massive revenue losses
to declining salesmay leadto declining sales
the overall sales risk(passive) caused bythe overall sales risk
to the increasing launch of generic drugsleadsto the increasing launch of generic drugs
to massive falls in sales of the originalleadsto massive falls in sales of the original
to onesetto one
the loss(passive) caused bythe loss
earnings and revenues to declineto causeearnings and revenues to decline
in stiff competition from other drugswill ... resultin stiff competition from other drugs
sales to drop by more thancan causesales to drop by more than
to manufacturing of genericsleadingto manufacturing of generics
to massive falls in sales of the original as generics steal market share etcleadsto massive falls in sales of the original as generics steal market share etc
in a smallcausein a small
to the manufacturing of generic drugs , which can be leveraged by the generic manufacturesleadsto the manufacturing of generic drugs , which can be leveraged by the generic manufactures
nothinginventednothing
for August 20 , 2020setfor August 20 , 2020
to the introduction of new biosimilarswill leadto the introduction of new biosimilars
to massive fallsleadsto massive falls
to an abrupt drop in sales Provisional patent application Submarine patent Supplementary protection certificate ( SPCleadsto an abrupt drop in sales Provisional patent application Submarine patent Supplementary protection certificate ( SPC
oftenresultsoften
to take place on october 15 , 2017is setto take place on october 15 , 2017
to the introduction of new entrantsleadingto the introduction of new entrants
to diminution of its market share ... but can not reasonably be considered either imminent or necessarily drastic as Keryx was the only company to apply for a new drug application and it was not yet approvedmay leadto diminution of its market share ... but can not reasonably be considered either imminent or necessarily drastic as Keryx was the only company to apply for a new drug application and it was not yet approved
to a loss in revenues of over USD 1bn ... EUR 734 m ... in 2008 ... due to generic sales erosionwill leadto a loss in revenues of over USD 1bn ... EUR 734 m ... in 2008 ... due to generic sales erosion
to the availability of highly similar , safe and effective biotech products that are more reasonably priced and more affordable for patients requiring treatment with such productsleadsto the availability of highly similar , safe and effective biotech products that are more reasonably priced and more affordable for patients requiring treatment with such products
to a 60 - 70 per cent crash in drug pricesusually leadsto a 60 - 70 per cent crash in drug prices
to a dramatic increase in its use , including applications to fields during growing seasonledto a dramatic increase in its use , including applications to fields during growing season
to a 35 % decrease in 2006 sales for depression drug Zoloft , Pfizer 's third - highest sellerledto a 35 % decrease in 2006 sales for depression drug Zoloft , Pfizer 's third - highest seller